Voting
Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing
866-314-3599.
View an enhanced version of our Annual Report.
View an enhanced version of our Notice of Meeting & Proxy Statement.
Request paper copies of the proxy materials online now, by email or by phone by dialing 866-648-8133.
Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing
866-314-3599.
Register for our virtual meeting. You must register to be eligible to join the meeting.
DATE: June 3, 2026
TIME: 11:30 AM ET
Kalaris is a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. The company is focused on development of TH103, a novel, clinical stage anti-vascular endothelial growth factor (“VEGF”) drug. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered to achieve extended intraocular retention with enhanced VEGF inhibition in patients with exudative and/or neovascular retinal diseases.